NASDAQ: NBSE - NeuBase Therapeutics, Inc.

Yield per half year: -15.72%
Sector: Healthcare

Share chart NeuBase Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene.

More details
NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

EBITDA -0.0031
EV/EBITDA -2.17
IPO date 2007-05-01
ISIN US64132K1025
Industry Biotechnology
P/BV 0.9603
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.neubasetherapeutics.com
Цена ао 0.4788
Change price per day: -0% (0.378)
Change price per week: -0% (0.378)
Change price per month: -0% (0.378)
Change price per 3 month: -0% (0.378)
Change price per half year: -15.72% (0.4485)
Change price per year: -53.28% (0.809)
Change price per 3 year: -90.36% (3.92)
Change price per 5 year: -91.8% (4.61)
Change price per year to date: -48.92% (0.74)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0.1914

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -89.87 0
Yield Ebitda, % 948.06 10
Yield EPS, % -95.53 0
Total: 6
More

Institutions Volume Share, %
Greenlight Capital, Inc. 136350 3.63
UBS Group AG 65724 1.75
Point72 Asset Management, L.P. 62500 1.67
Renaissance Technologies, LLC 56967 1.52
Carnegie Mellon University 46970 1.25
Two Sigma Investments, LP 21083 0.56
Vanguard Group Inc 18981 0.51
Kestra Advisory Services, LLC 16476 0.44
Jacob Asset Management Of New York LLC 15655 0.42
Prelude Capital Management LLC 15550 0.41



Head Job title Payment Year of birth
Dr. Dietrich A. Stephan Ph.D. Founder, President & Director 836.58k 1970 (54 years)
Mr. Todd P. Branning Interim CEO, CFO & Secretary 427.44k 1970 (54 years)

Address: United States, Pittsburgh. PA, 350 Technology Drive - open in Google maps, open in Yandex maps
Website: https://www.neubasetherapeutics.com